


What is claimed is:

1. A method of treating cancer comprising administering to a patient in need thereof an effective amount of a compound of Formula I:



wherein,

each R is independently hydrogen, hydroxy, alkyl, aryl, cycloalkyl, heteroaryl, alkoxy, heterocyclic or amino;

each R₁ is independently alkyl, halo, alkoxy, haloalkyl, haloalkoxy, cycloalkyl, heterocyclic, hydroxy, -C(O)-R₈, -NR₉R₁₀, -NR₉C(O)-R₁₂ or -C(O)NR₉R₁₀;

each R₂ is independently alkyl, aryl, heteroaryl, -C(O)-R₈ or SO₂R'', where R'' is alkyl, aryl, heteroaryl, NR₉N₁₀ or alkoxy;

each R₅ is independently hydrogen, alkyl, aryl, haloalkyl, cycloalkyl, heteroaryl, heterocyclic, hydroxy, -C(O)-R₈ or (CHR)_rR₁₁;

X is O or S;

j is 0 or 1;

p is 0, 1, 2 or 3;

q is 0, 1 or 2;

r is 0, 1, 2 or 3;


R₈ is hydroxy, alkyl, aryl, heteroaryl, alkoxy, cycloalkyl or heterocyclic;

R₉ and R₁₀ are independently hydrogen, alkyl, aryl, aminoalkyl, heteroaryl, cycloalkyl and heterocyclic, or R₉ and R₁₀ together with N may form a ring, where the ring atoms are selected from the group consisting of C, N, O and S;

R₁₁ is hydroxy, amino, monosubstituted amino, disubstituted amino, alkyl, aryl, heteroaryl, alkoxy, cycloalkyl or heterocyclic

R₁₂ is alkyl, aryl, heteroaryl, alkoxy, cycloalkyl or heterocyclic; and

Z is hydroxy, -O-alkyl, or -NR₃R₄, where R₃ and R₄ are independently hydrogen, alkyl, aryl, heteroaryl, cycloalkyl, or heterocyclic, or R₃ and R₄ may combine with N to form a ring where the ring atoms are selected from the group consisting of CH₂, N, O and S, or




wherein Y is independently CH₂, O, N or S, Q is C or N, n is independently 0, 1, 2, 3 or 4, and m is 0, 1, 2 or 3;

or a pharmaceutically acceptable salt, hydrate or solvate thereof, in combination with at least one chemotherapeutic agent selected from the group consisting of microtubule interference agents, topoisomerase inhibitors, alkylating agents, thymidylate synthase inhibitors, irreversible steroidal aromatase inactivators, anti-metabolites, pyrimidine antagonists, purine antagonists, ribonucleotide reductase inhibitors, and kinase inhibitors.

2. The method of claim 1, wherein R₁ is halo and p is 1.
3. The method of claim 1, wherein R₁ is F or Cl and p is 1.
4. The method of claim 1, wherein Z is -NR₃R₄ wherein R₃ and R₄ are lower alkyl or form a morpholine ring.


5. The method of claim 1, wherein Z is:



wherein each Y is CH₂, each n is 2, m is 0 and R₃ and R₄ form a morpholine ring.


6. The method of claim 1, wherein R₂ is methyl and q is 2, wherein the methyls are bonded at the 3 and 5 positions.

7. The method of claim 1, wherein the compound of formula I is selected from the group consisting of




and pharmaceutically acceptable salts, solvates and hydrates thereof.

8. The method of claim 1, wherein the compound of formula I is selected from the group consisting of:



and pharmaceutically acceptable salts, solvates and hydrates thereof.

9. The method of claim 1, wherein the compound of Formula (I) is:



or a pharmaceutically acceptable salt, solvate or hydrate thereof.

10. The method of claim 9, wherein the salt is a malate salt.

11. The method of claim 1, wherein the at least one chemotherapeutic agent is selected from the group consisting of taxanes, vinca alkyls, topoisomerase I inhibitors and topoisomerase II inhibitors.

12. The method of claim 1, wherein the at least one chemotherapeutic agent is selected from the group consisting of paclitaxel, docetaxel, vinblastine, vincristine, vindesine, irinotecan, doxorubicin, epirubicin, leucovorin, etoposide, teniposide, idarubicin, gemcitabine, daunorubicin, carboplatin, cisplatin, oxaliplatin, chlorambucil, melphalan, cyclophosphamide, ifosfamide, temozolomide, thiotepa, mitomycin C, busulfan, carmustine, lomustine, 5-fluorouracil, capecitabine, exemestane, methotrexate, trimetrexate, fluorouracil, fluorodeoxyuridine, azacytidine, mercaptopurine, thioguanine, pentostatin, cytarabine, fludarabine, hydroxyurea, bevacizumab, cetuximab, gefitinib and imatinib.

13. The method of claim 1, wherein the cancer is breast cancer, small cell lung carcinoma, colon cancer, non-small cell lung cancer, renal cell cancer, a gastrointestinal stromal tumor, thyroid cancer, a sarcoma or a neuroendocrine tumor.

14. The method of claim 1, wherein the cancer is non-small cell lung cancer and the at least one chemotherapeutic agent is carboplatin and paclitaxel.

15. The method of claim 1, wherein the cancer is non-small cell lung cancer and the at least one chemotherapeutic agent is carboplatin, taxotere, cisplatin, gemcitabine, 5-fluorouracil, irinotecan or leucovorin.

16. The method of claim 1, wherein the cancer is colon cancer and the at least one chemotherapeutic agent is 5-fluorouracil, oxaliplatin or leucovorin.

17. A method of treating cancer comprising administering to a patient in need thereof an effective amount of a compound selected from the group consisting of:

5-(5-Fluoro-2-oxo-1,2-dihydro-indol-3-ylidenemethyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylamino-ethyl)-amide;

5-(5-Fluoro-2-oxo-1,2-dihydro-indol-3-ylidenemethyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-pyrrolidin-1-yl-ethyl)-amide;

5-(5-Fluoro-2-oxo-1,2-dihydro-indol-3-ylidenemethyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-morpholin-4-yl-ethyl)-amide;

(S)-5-(5-Fluoro-2-oxo-1,2-dihydro-indol-3-ylidenemethyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-hydroxy-3-morpholin-4-yl-propyl)-amide;

(R)-5-(5-Fluoro-2-oxo-1,2-dihydro-indol-3-ylidenemethyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-hydroxy-3-morpholin-4-yl-propyl)-amide;

5-(5-Fluoro-2-oxo-1,2-dihydro-indol-3-ylidenemethyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-hydroxy-3-morpholin-4-yl-propyl)-amide;

5-(5-Chloro-2-oxo-1,2-dihydro-indol-3-ylidenemethyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-hydroxy-3-morpholin-4-yl-propyl)-amide;

5-(5-Fluoro-2-oxo-1,2-dihydro-indol-3-ylidenemethyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-ethylamino-ethyl)-amide; and

3-[3,5-dimethyl-4-(4-morpholin-4-yl-piperidine-1-carbonyl)-1H-pyrrol-2-methylene]-5-fluoro-1,3-dihydro-indol-2-one,

or a pharmaceutically acceptable salt, hydrate or solvate thereof, in combination with at least one chemotherapeutic agent selected from the group consisting of microtubule interference agents, topoisomerase inhibitors, alkylating agents, thymidylate synthase inhibitors, irreversible steroidal aromatase inactivators, anti-metabolites, pyrimidine antagonists, purine antagonists, ribonucleotide reductase inhibitors, and kinase inhibitors.

18. The method of claim 17, wherein the at least one chemotherapeutic agent is selected from the group consisting of taxanes, vinca alkyloids, topoisomerase I inhibitors and topoisomerase II inhibitors.

19. The method of claim 17, wherein the at least one chemotherapeutic agent is selected from the group consisting of paclitaxel, docetaxel, vinblastine, vincristine, vindesine, irinotecan, doxorubicin, epirubicin, leucovorin, etoposide, teniposide, idarubicin, gemcitabine, daunorubicin, carboplatin, cisplatin, oxaliplatin, chlorambucil, melphalan, cyclophosphamide, ifosfamide, temozolomide, thiotepa, mitomycin C, busulfan, carmustine, lomustine, 5-fluorouracil, capecitabine, exemestane, methotrexate, trimetrexate, fluorouracil, fluorodeoxyuridine, azacytidine, mercaptopurine, thioguanine, pentostatin, cytarabine, fludarabine, hydroxyurea, bevacizumab, cetuximab, gefitinib and imatinib.

20. The method of claim 17, wherein the cancer is breast cancer, small cell lung carcinoma, colon cancer, non-small cell lung cancer, renal cell cancer, a gastrointestinal stromal tumor, thyroid cancer, a sarcoma or a neuroendocrine tumor.